Efficacy and Safety of Cyclophosphamide in Pediatric Patients With Steroid-Refractory Acute Disseminated Encephalomyelitis (ADEM) (CYC-ADEM-Peds)
A Randomized, Open-Label, Comparative Clinical Trial Evaluating the Efficacy and Safety of Cyclophosphamide Versus Intravenous Immunoglobulin (IVIG) in Pediatric Patients With Steroid-Refractory Acute Disseminated Encephalomyelitis
Acute Disseminated Encephalomyelitis (ADEM) is a severe, immune-mediated demyelinating disease of the central nervous system predominantly affecting the pediatric population. Although high-dose intravenous corticosteroids (such as methylprednisolone) represent standard first-line therapy, a subset of clinical cases fails to achieve adequate clinical response, carrying high risks of persistent neurological disability, neurodevelopmental sequelae, or fulminant deterioration.
This randomized, open-label trial evaluates the clinical efficacy, neuroimaging outcomes, and safety profile of intravenous cyclophosphamide pulse therapy compared with intravenous immunoglobulin (IVIG) as a rescue modality in pediatric patients under 14 years of age with steroid-refractory ADEM. Eligible participants are allocated using a computer-based random number generator. Enrolled patients are prospectively monitored for neurological recovery, functional disability using the pediatric Liverpool Outcome Score (LOS), radiological resolution on neuroimaging (MRI), overall survival, and treatment-emergent adverse events.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Acute Disseminated Encephalomyelitis (ADEM) is an immune-mediated demyelinating inflammatory disorder of the central nervous system predominantly affecting pediatric patients. While high-dose intravenous corticosteroids (such as methylprednisolone) serve as the standard first-line treatment, a clinical subset of patients fails to respond, presenting persistent neurological deficits, neurodevelopmental sequelae, or fulminant clinical deterioration.
This prospective, randomized, open-label comparative clinical trial is designed to evaluate the therapeutic efficacy, neuroimaging resolution, and safety profile of intravenous cyclophosphamide pulse therapy compared with intravenous immunoglobulin (IVIG) as a standard second-line immunomodulatory therapy in pediatric patients under 14 years of age with steroid-refractory ADEM.
Eligible participants (a total of 30 pediatric patients) are randomized in a 1:1 ratio using a computer-generated random number sequence into two equal treatment arms: 15 patients in the experimental arm receive intravenous cyclophosphamide pulse therapy (500 mg/m2) combined with intensive hydration and Mesna uroprotection to prevent hemorrhagic cystitis, while 15 patients in the active comparator arm receive standard intravenous immunoglobulin (IVIG) immunomodulatory therapy (2 g/kg).
Longitudinal monitoring is performed across both cohorts to assess neurological functional recovery and disability using the pediatric-validated Liverpool Outcome Score (LOS), radiological clearance on brain and spine MRI, overall survival up to 24 months, and the active surveillance of treatment-emergent adverse events.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Fatima Amer, MD
- Telefoonnummer: +963 966494768
- E-mail: Fatema.amer@damascusuniversity.edu.sy
Studie Locaties
-
-
-
Damascus, Syrië
- Werving
- Children's University Hospital
-
Contact:
- Fatima Amer, MD
- Telefoonnummer: +963 966494768
- E-mail: Fatema.amer@damascusuniversity.edu.sy
-
Hoofdonderzoeker:
- Fatima Amer, MD
-
Hoofdonderzoeker:
- Sameer Baqla, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Pediatric patients younger than 14 years of age (< 14 years) at clinical presentation.
- Confirmed diagnosis of Acute Disseminated Encephalomyelitis (ADEM) fulfilling the consensus criteria defined by the International Pediatric Multiple Sclerosis Study Group (IPMSSG).
- Steroid-refractory clinical status, defined as active disease persistence, neurological deterioration, or absence of significant functional improvement following a 3-5 day course of high-dose intravenous methylprednisolone pulse therapy (20-30 mg/kg/day).
- Intact baseline renal function (serum creatinine and BUN within age-adjusted normal physiological ranges).
- Intact baseline hepatic function (AST, ALT, and bilirubin within acceptable limits).
- Absence of active systemic sepsis, bacteremia, or acute uncontrolled systemic infection at baseline.
- Formal written informed consent obtained from parents or legal guardians.
Exclusion Criteria:
- Patients aged 14 years and older (≥ 14.0 years).
- Pre-existing significant renal insufficiency, acute kidney injury, or chronic renal disease.
- Pre-existing hepatic failure, cirrhosis, or acute severe hepatic injury.
- Active systemic sepsis or uncontrolled severe systemic infection.
- Pre-existing severe bone marrow suppression (baseline absolute neutrophil count ANC ≤ 1500/mm³ or platelet count < 50,000/mm³).
- History of known hypersensitivity to cyclophosphamide, Mesna, or immunoglobulin preparations.
- Alternative neuroinflammatory or metabolic diagnosis confirmed.
- Refusal of parents or legal guardians to grant written informed consent.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Cyclophosphamide IV
Fifteen pediatric patients (<14 years) with steroid-refractory ADEM randomized to this experimental group will receive intravenous cyclophosphamide pulse therapy as rescue treatment. |
Administered as intravenous pulse therapy at a dosage of 500 mg/m² body surface area. Delivered with intensive pre- and post-hydration protocols along with Mesna (2-mercaptoethane sulfonate sodium) uroprotection to mitigate acrolein-induced hemorrhagic cystitis. |
|
Actieve vergelijker: Intravenous Immunoglobulin (IVIG)
Fifteen pediatric patients (<14 years) with steroid-refractory ADEM randomized to this active comparator group receive intravenous immunoglobulin (IVIG) as a standard second-line immunomodulatory therapy for ADEM. |
Administered at a total immunomodulatory dose of 2 g/kg body weight, infused according to standard pediatric institutional protocols (either 1 g/kg/day for 2 consecutive days or 400 mg/kg/day over 5 consecutive days), under continuous hemodynamic monitoring. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Neurological Functional Outcome and Disability Assessment by Liverpool Outcome Score (LOS)
Tijdsspanne: Assessed at hospital discharge, and longitudinally at 2, 4, and 12 weeks post-treatment initiation.
|
Evaluation of functional recovery and post-encephalitic neurological sequelae using the pediatric-validated Liverpool Outcome Score (LOS). The LOS stratifies pediatric neuro-outcomes into 5 distinct categories:
|
Assessed at hospital discharge, and longitudinally at 2, 4, and 12 weeks post-treatment initiation.
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Radiological Resolution on Neuroimaging (Brain & Spine MRI)
Tijdsspanne: Assessed at 2,4 and 12 weeks post-treatment initiation.
|
Quantitative and qualitative reduction or total resolution of hyperintense demyelinating lesions on T2/FLAIR sequences, resolution of contrast enhancement, and absence of new active or demyelinating lesions. |
Assessed at 2,4 and 12 weeks post-treatment initiation.
|
|
Overall Survival and All-Cause Mortality Rate
Tijdsspanne: Up to 24 months
|
Proportion of pediatric patients surviving without fatal disease complications or fulminant progression throughout the study observation window. |
Up to 24 months
|
|
Treatment-Emergent Adverse Events & Tolerability
Tijdsspanne: Inpatient stay and longitudinally at 1, 2, and 12 weeks post-treatment initiation.
|
Incidence and severity of adverse drug reactions including bone marrow suppression (CBC) and hemorrhagic cystitis (Urinalysis) |
Inpatient stay and longitudinally at 1, 2, and 12 weeks post-treatment initiation.
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Fatima Amer, MD, Department of Pediatric Neurology, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic
- Studie directeur: Sameer Baqla, PhD, Department of Pediatric Neurology, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic
- Studie directeur: Sally Kadoura, PhD, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syrian Arab Republic
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Post-infectieuze aandoeningen
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Pathologische processen
- Chronische ziekte
- Ziekte attributen
- Auto-immuunziekten
- Ziekten van het immuunsysteem
- Auto-immuunziekten van het zenuwstelsel
- Demyeliniserende ziekten
- Leuko-encefalopathieën
- Pathologische aandoeningen, tekenen en symptomen
- Demyeliniserende auto-immuunziekten, CZS
- Encefalomyelitis, acuut gedissemineerd
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Organische chemicaliën
- Koolwaterstoffen
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Fosforamide mosterd
- Stikstofmosterdverbindingen
- Mosterdverbindingen
- Koolwaterstoffen, gehalogeneerd
- Fosforamides
- Organofosforverbindingen
- Immunoglobuline -isotypes
- Immunoglobuline G
- Cyclofosfamide
- Immunoglobulinen, intraveneus
Andere studie-ID-nummers
Andere studie-ID-nummers
- MD-051124-349
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .